Arcutis Biotherapeutics 

Yahoo Finance • 5 days ago

Netflix target cut, Five Below target raised: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Price Target Raises: UBS raised the firm's price... Full story

Yahoo Finance • 16 days ago

FDA Accepts Arcutis' SNDA To Expand Zoryve Use To Children Aged 2-5

(RTTNews) - Commercial-stage biopharmaceutical company Arcutis Biotherapeutics, Inc. (ARQT), on Monday, said that the FDA has accepted a supplemental New Drug Application (sNDA) for Zoryve (roflumilast) cream, a once-daily, advanced target... Full story

Yahoo Finance • 16 days ago

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2 WESTLAKE VILLAGE, Ca... Full story

Yahoo Finance • 26 days ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the... Full story

Yahoo Finance • last month

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin healthZORYVE® (roflumilast) is the #1 prescribed branded topical therapy for three major inflammatory... Full story

Yahoo Finance • last month

Arcutis (ARQT) Soars to Record High on Swing to Profitability, ‘More-Than-Double’ Revenues

We recently published 10 Stocks Soaring by Double Digits; Uranium Stocks Leading. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the top-performing stocks on Tuesday. Arcutis jumped to a fresh record high on Tuesday, as investors ch... Full story

Yahoo Finance • last month

Noteworthy Tuesday Option Activity: CGON, DECK, ARQT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CG Oncology Inc (Symbol: CGON), where a total of 4,018 contracts have traded so far, representing approximately 401,800 underlying... Full story

Yahoo Finance • last month

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and Drug Administration (FDA) approval for the... Full story

Yahoo Finance • last month

Arcutis to Present at Upcoming Investor Conferences

WESTLAKE VILLAGE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced th... Full story

Yahoo Finance • last month

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference

New data from Phase 3 studies show once-daily ZORYVE cream helped reduce sleep disruptions in individuals with atopic dermatitis aged ≥2 yearsNew long-term data demonstrate that ZORYVE cream was well-tolerated and provided continued diseas... Full story

Yahoo Finance • 2 months ago

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025... Full story

Yahoo Finance • 2 months ago

Biotech Leader Arcutis Is Breaking Out, Up Nearly 36% in 2025

Biotech leader Arcutis stock is breaking out past its latest buy point. Shares are up nearly 36% in 2025. Continue Reading View Comments... Full story

Yahoo Finance • 3 months ago

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin typesNew data show improved quality of life and decreased impact on families for investigational ZORYVE... Full story

Yahoo Finance • 3 months ago

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Technical Strength with High Growth Momentum

In the world of growth investing, combining technical strength with fundamental momentum often yields promising candidates. One approach gaining traction is the integration of Mark Minervini’s Trend Template with high growth momentum (HGM)... Full story

Yahoo Finance • 3 months ago

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to topical steroids and vitamin-D analogsZORYV... Full story

Yahoo Finance • 3 months ago

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide exp... Full story

Yahoo Finance • 4 months ago

This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine

Biotech stocks are performing well in the stock market in August and a few in the IBD 50 have formed bases with clear buy points. Continue Reading View Comments... Full story

Yahoo Finance • 4 months ago

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Fits the Minervini Trend Template with Strong Growth Momentum

SPOTTING HIGH-GROWTH STOCKS USING THE MINERVINI TREND TEMPLATE Mark Minervini’s Trend Template is a structured method for finding stocks in strong upward trends, blending technical and fundamental factors to select promising options. The... Full story

Yahoo Finance • 4 months ago

Earnings call transcript: Arcutis Q2 2025 beats EPS and revenue forecasts

Arcutis Biotherapeutics reported its earnings for the second quarter of 2025, surpassing both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.13, beating the forecast of -$0.17, and reported revenue of $81.... Full story

Yahoo Finance • 4 months ago

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

WESTLAKE VILLAGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced th... Full story